Stock 719 SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Shandong Xinhua Pharmaceutical Company Limited

Equities

719

CNE100000411

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:57 25/06/2024 BST 		5-day change 1st Jan Change
5.36 HKD +0.94% Intraday chart for Shandong Xinhua Pharmaceutical Company Limited -2.72% -7.27%
06-20 Xinhua Pharmaceutical Gets Nod to Register Pregabalin Capsules MT
06-19 Shandong Xinhua Pharmaceutical Company Limited Obtains Drug Registration Certificate on Pregabalin Capsules CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Xinhua Pharmaceutical Gets Nod to Register Pregabalin Capsules
MT
Shandong Xinhua Pharmaceutical Company Limited Obtains Drug Registration Certificate on Pregabalin Capsules
CI
Shandong Xinhua Pharmaceutical's Two Drugs Pass Chinese Drug Regulator's Consistency Evaluation
MT
Shandong Xinhua Pharmaceutical Company Limited Receives the Notice of Approval of Supplementary Drug Application from the National Medical Products Administration
CI
Shandong Xinhua Pharmaceutical Company Limited Receives the Notice of Approval of Supplementary Drug Application from the National Medical Products Administration
CI
Xinhua Pharmaceutical’s Sodium Bicarbonate Injection Passes Generic Drug Evaluation in China
MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration
CI
Xinhua Pharmaceutical's Depression Drug Gets Registration Approval in China
MT
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of Escitalopram Oxalate Tablets
CI
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation
MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application
CI
Shandong Xinhua Pharmaceutical Posts Higher 2023 Profit
MT
Shandong Xinhua Pharmaceutical Proposes New Auditor
MT
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023
CI
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Xinhua Pharma's Ibuprofen Gets Registration Approval in China
MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient
CI
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate
CI
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 719 Stock
  4. News Shandong Xinhua Pharmaceutical Company Limited